Deformable Image Registration for Breast Adaptive Tomotherapy
NCT ID: NCT05383144
Last Updated: 2023-04-07
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
40 participants
OBSERVATIONAL
2022-06-27
2023-04-04
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Quantitative Evaluation of the Breast's Morphological Variations During Radiotherapy: MorphoBreast3D
NCT03801850
Prospective Validation of 3D Dose Metrics as Selection Criteria for Adaptive Radiotherapy in Breast Cancer Patients
NCT03385031
Evaluation of Tomosynthesis for Characterization and the Management of Breast Lesions
NCT02959398
Study First Step to Virtual Breast Cancer Localization
NCT03214419
4D CT Scan Versus 3D CT Scan Concerning Cardiac Dosimetry Assesment for Left Sided Breast Cancers Radiotherapy
NCT05726604
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Complete Positioning scans
Entire treatment zone imaging at mi-treatment and at end of treatment
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* With invasive breast carcinoma (or axillary lymphadenopathy whose pathological examination is compatible with the origin of breast cancer but without an identified primary breast tumor)
* Breast surgery (conservative surgery or mastectomy)
* Treated by (neo)adjuvant chemotherapy or hormonotherapy
* eligible to normo-fractionated breast radiotherapy in 25 sessions of 2 Gray or 15 sessions of 2.67 Gray, associated or not to bed irradiation whatever the delivered dose
* eligible to an irradiation of sus-clavicular, inner mammary chain or axillary lymph nodes
* With helicoidal tomotherapy
Exclusion Criteria
* Absence of indication for lymph nodes irradiation
* partial irradiation of breast
* in situ carcinoma
* intranodal isolated tumor cells
* radiotherapy on prosthesis or surgically reconstructed breast
* antecedent of breast irradiation opr homolateral lymh node irradiation
* bilateral breast cancer
18 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Institut de cancérologie Strasbourg Europe
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Institut de cancérologie Strasbourg Europe
Strasbourg, , France
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2022-001
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.